

Steffin DHM, Muhsen IN, Hill LC, et al. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. *Blood*. 2022;140(1):16-24.

In "Acknowledgments" on pages 22-23, support provided by the National Gene Vector Biorepository at Indiana University under National Heart, Lung, and Blood Institute contract 75N92019D00018 should have been cited.

<https://doi.org/10.1182/blood.2022019334>

© 2023 by The American Society of Hematology. Licensed under [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International \(CC BY-NC-ND 4.0\)](https://creativecommons.org/licenses/by-nc-nd/4.0/), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Vaxman I, Gertz MA. How I approach smoldering multiple myeloma. *Blood*. 2022;140(8):828-838.

On page 830, in the last row of the rightmost column of Table 2, the low/intermediate risk should be 26.2%, not 51.1%, and the intermediate risk should be 51.1%, not 26.2%.

<https://doi.org/10.1182/blood.2022019523>

© 2023 by The American Society of Hematology. Licensed under [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International \(CC BY-NC-ND 4.0\)](https://creativecommons.org/licenses/by-nc-nd/4.0/), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Lew TE, Tam CS, Seymour JF. How I treat chronic lymphocytic leukemia after venetoclax. *Blood*. 2021;138(5):361-369.

Page 365: In the paragraph that begins "On longer-term follow-up," the phrase "time of venetoclax" should read "time off venetoclax" in the sentence "In an update from the MURANO study, among 18 response-evaluable patients with a median time of venetoclax of 24 months, the ORR to retreatment was 72%, with 50% of patients remaining on therapy after a median of 11 months."

<https://doi.org/10.1182/blood.2023019924>

© 2023 by The American Society of Hematology